Celltrion acquires sales approval of antibody biosimilar ‘Truxima’ in Korea
Celltrion announced it acquired sales approval of its self-developed antibody biosimilar, CT-P10(brand name: Truxima, generic name: rituximab), from the Korea Ministry of Food and Drug Safety(MFDS) on the 16th.
The MFDS approved Truxima to be used in indications, such as non-Hodgkin lymphomas, ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
